Reviewer's report

**Title:** Cancer risk among elderly persons with end-stage renal disease: a population-based case-control study

**Version:** 1  **Date:** 10 May 2012

**Reviewer:** Kuan-Yu Hung

**Reviewer's report:**

The value of this work may be the screening awareness of associated malignancy in ESRD patients. But as shown in Table 2, it's too diverse to have a screening suggestion to physicians caring these ESRD patients.

1. In order to be more focusing, can we just enroll GU-tract malignancy?, as these are biologically relevant and can possibly be explained by underlying immune dysfunction or else.

2. For those with multiple myeloma (MM), can we analyze further whether these patients have longer duration of MM? Can it be possible that it's the MM that lead to ESRD in these patients?

3. For prostate cancer (Table 3), do you suggest that ESRD patients receive PSA survey on a regular basis?, and the frequency? It's a clinically important and practical issue.

**Level of interest:** An article of importance in its field

**Quality of written English:** Acceptable

**Statistical review:** Yes, but I do not feel adequately qualified to assess the statistics.

**Declaration of competing interests:**

Nil